dbo:abstract
|
- هيلين هوبز (بالإنجليزية: Helen Hobbs) هي عالمة كيمياء حيوية وأستاذة جامعية وطبيبة أمريكية، ولدت في 5 مايو 1952 في بوسطن في الولايات المتحدة. (ar)
- Helen Haskell Hobbs (* 5. Mai 1952 in Boston, Massachusetts) ist eine US-amerikanische Genetikerin und Stoffwechselforscherin am in Dallas. Sie gilt als führend in der Genetik der Hypercholesterinämie und Dyslipoproteinämie. (de)
- Helen Haskell Hobbs, M.D., (born May 5, 1952 in Boston, Massachusetts) is a professor at the University of Texas Southwestern Medical Center, and a Howard Hughes Medical Institute Investigator, who won a 2016 Breakthrough Prize in Life Sciences and the 2018 Harrington Prize for Innovation in Medicine. She and Jonathan C. Cohen found that people with hypomorphic PCSK9 mutations had lower LDL-cholesterol levels and were almost immune to heart disease. This finding led to the development of a new class of cholesterol-lowering drugs that mimic the effects of the PCSK9 mutations. She and Jonathan Cohen also identified the first genetic risk factor for fatty liver disease, a burgeoning health problem that can lead to cirrhosis and liver cancer. Their laboratory has shown that mutation in PNPLA3 causes accumulation of PNPLA3 on lipid droplets, which compromises the mobilization of triglycerides from liver cells. She sits on the Board of Directors at Pfizer. (en)
- Helen Hobbs, née en 1952, est une biologiste moléculaire et généticienne américaine. Elle est professeure et directrice de recherche à l'École médicale du Sud-Ouest de l'université du Texas et au Howard Hughes Medical Institute. En 2016, elle a reçu le Breakthrough Prize in Life Sciences pour la découverte de variantes génétiques, qui modifient les niveaux et la distribution du cholestérol et autres lipides dans le corps humain. Cela a inspiré de nouvelles approches dans la prévention des maladies cardiovasculaires et des maladies du foie. (fr)
- Хелен Хоббс (Helen Haskell Hobbs; род. 5 мая 1952, Бостон, Массачусетс) — американский учёный-медик, генетик.Профессор и исследователь Медицинского института Говарда Хьюза, член Национальных Академии наук (2007) и (2004) США. (ru)
- Helen Hobbs é uma médica estadunidense. É professora da University of Texas Southwestern Medical Center, e pesquisadora do Instituto Médico Howard Hughes. Recebeu o Breakthrough Prize in Life Sciences de 2016. (pt)
|
dbo:wikiPageExternalLink
| |
dbo:wikiPageID
| |
dbo:wikiPageLength
|
- 6729 (xsd:nonNegativeInteger)
|
dbo:wikiPageRevisionID
| |
dbo:wikiPageWikiLink
| |
dbp:wikiPageUsesTemplate
| |
dcterms:subject
| |
gold:hypernym
| |
schema:sameAs
| |
rdf:type
| |
rdfs:comment
|
- هيلين هوبز (بالإنجليزية: Helen Hobbs) هي عالمة كيمياء حيوية وأستاذة جامعية وطبيبة أمريكية، ولدت في 5 مايو 1952 في بوسطن في الولايات المتحدة. (ar)
- Helen Haskell Hobbs (* 5. Mai 1952 in Boston, Massachusetts) ist eine US-amerikanische Genetikerin und Stoffwechselforscherin am in Dallas. Sie gilt als führend in der Genetik der Hypercholesterinämie und Dyslipoproteinämie. (de)
- Helen Hobbs, née en 1952, est une biologiste moléculaire et généticienne américaine. Elle est professeure et directrice de recherche à l'École médicale du Sud-Ouest de l'université du Texas et au Howard Hughes Medical Institute. En 2016, elle a reçu le Breakthrough Prize in Life Sciences pour la découverte de variantes génétiques, qui modifient les niveaux et la distribution du cholestérol et autres lipides dans le corps humain. Cela a inspiré de nouvelles approches dans la prévention des maladies cardiovasculaires et des maladies du foie. (fr)
- Хелен Хоббс (Helen Haskell Hobbs; род. 5 мая 1952, Бостон, Массачусетс) — американский учёный-медик, генетик.Профессор и исследователь Медицинского института Говарда Хьюза, член Национальных Академии наук (2007) и (2004) США. (ru)
- Helen Hobbs é uma médica estadunidense. É professora da University of Texas Southwestern Medical Center, e pesquisadora do Instituto Médico Howard Hughes. Recebeu o Breakthrough Prize in Life Sciences de 2016. (pt)
- Helen Haskell Hobbs, M.D., (born May 5, 1952 in Boston, Massachusetts) is a professor at the University of Texas Southwestern Medical Center, and a Howard Hughes Medical Institute Investigator, who won a 2016 Breakthrough Prize in Life Sciences and the 2018 Harrington Prize for Innovation in Medicine. She and Jonathan C. Cohen found that people with hypomorphic PCSK9 mutations had lower LDL-cholesterol levels and were almost immune to heart disease. This finding led to the development of a new class of cholesterol-lowering drugs that mimic the effects of the PCSK9 mutations. She and Jonathan Cohen also identified the first genetic risk factor for fatty liver disease, a burgeoning health problem that can lead to cirrhosis and liver cancer. Their laboratory has shown that mutation in PNPLA3 (en)
|
rdfs:label
|
- هيلين هوبز (ar)
- Helen Hobbs (de)
- Helen Hobbs (fr)
- Helen Hobbs (en)
- Helen Hobbs (pt)
- Хоббс, Хелен (ru)
|
owl:sameAs
| |
prov:wasDerivedFrom
| |
foaf:isPrimaryTopicOf
| |
is dbo:wikiPageRedirects
of | |
is dbo:wikiPageWikiLink
of | |
is foaf:primaryTopic
of | |